- Zenakine is a biotech-based neuroactive ingredient developed by Croda and SkinBiotherapeutics.
- It was first introduced at in-cosmetics Global, the largest cosmetics ingredients exhibition.
- Zenakine enhances melatonin production to improve sleep quality and combat stress ageing.
- It is fully biodegradable and compliant with COSMOS and RSPO standards.
Introduction
On 8 September 2025, Croda International Plc launched Zenakine™, a biotech-based neuroactive ingredient aimed at mitigating the effects of stress on the skin.
Development and Launch
Zenakine is based on research by the translational dermatology team at the University of Manchester and was further developed by SkinBiotherapeutics plc. It was first introduced at in-cosmetics Global, the world's largest cosmetics ingredients exhibition.
Functionality
This ingredient is designed to work with the skin's natural biological rhythms, enhancing melatonin production to improve sleep quality, combat stress ageing, and support overall wellbeing.
Sustainability
Zenakine is fully biodegradable and meets COSMOS and RSPO standards. It is developed using renewable feedstocks, aligning with Croda's commitment to environmental stewardship.
